Biopharma developing a birch-pollen allergy vaccine.
| Date | Round | Amount |
|---|---|---|
| Feb 2024 | Funding round Desentum, an Espoo allergy-vaccine biotech, raised EUR12M led by Springvest. | $13M |
| Feb 2022 | Funding round Espoo biotech Desentum raised 8M euros from Springvest to develop novel allergen immunotherapy vaccines. | $8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.